{"id":110654,"date":"2026-05-06T16:00:51","date_gmt":"2026-05-06T14:00:51","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/"},"modified":"2026-05-11T10:26:25","modified_gmt":"2026-05-11T08:26:25","slug":"mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/","title":{"rendered":"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: &#8220;We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules&#8221;"},"content":{"rendered":"<p>Nuage Therapeutics is a biotech spin-off that has developed an innovative technology to study intrinsically disordered proteins (IDPs) for the development of a new generation of transformative therapies. This strategy opens a new avenue for designing therapies targeting proteins that were previously considered undruggable.<\/p>\n<p>&#8220;What sets us apart is that we have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules,&#8221; explains <strong>Mireia Pesarrodona<\/strong>, Screening Platform Manager at Nuage Therapeutics, in this interview. The company\u2019s patented platform enables deeper insight into the transient structures adopted by IDPs. This allows researchers to design drugs capable of recognizing and acting on them\u2014something that was previously impossible. This discovery represents a paradigm shift in drug discovery, turning protein \u201cdisorder\u201d into a therapeutic opportunity.<\/p>\n<p>The company, founded by researchers from IRB Barcelona and ICREA, combines cutting-edge basic research with a strong translational focus. Since its inception, Nuage Therapeutics has been committed to building a robust technological platform capable of identifying and characterizing interactions in intrinsically disordered proteins with unprecedented precision. &#8220;At the beginning, we sought external support to implement technologies, thinking they would provide all the knowledge and expertise. However, we later realized that we ourselves have contributed a great deal of knowledge about this specific type of protein,&#8221; the researcher states.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nuage Therapeutics is a biotech spin-off that has developed an innovative technology to study intrinsically disordered proteins (IDPs) for the development of a new generation of transformative therapies. This strategy&#8230;<\/p>\n","protected":false},"author":14,"featured_media":110646,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[38],"tags":[294],"class_list":["post-110654","post","type-post","status-publish","format-standard","has-post-thumbnail","category-pcb-en","tag-nuage-therapeutics-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: &quot;We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules&quot; - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"We interviewed Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics, at the latest edition of the Coffee Connection meeting.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: &quot;We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules&quot; - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"We interviewed Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics, at the latest edition of the Coffee Connection meeting.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T14:00:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-11T08:26:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: &#8220;We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules&#8221;\",\"datePublished\":\"2026-05-06T14:00:51+00:00\",\"dateModified\":\"2026-05-11T08:26:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/\"},\"wordCount\":249,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/mini_nuage_noti-1.jpg\",\"keywords\":[\"Nuage Therapeutics\"],\"articleSection\":[\"PCB\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/\",\"name\":\"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: \\\"We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules\\\" - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/mini_nuage_noti-1.jpg\",\"datePublished\":\"2026-05-06T14:00:51+00:00\",\"dateModified\":\"2026-05-11T08:26:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"description\":\"We interviewed Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics, at the latest edition of the Coffee Connection meeting.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/mini_nuage_noti-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/mini_nuage_noti-1.jpg\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: &#8220;We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: \"We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules\" - Parc Cient\u00edfic de Barcelona","description":"We interviewed Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics, at the latest edition of the Coffee Connection meeting.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/","og_locale":"en_US","og_type":"article","og_title":"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: \"We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules\" - Parc Cient\u00edfic de Barcelona","og_description":"We interviewed Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics, at the latest edition of the Coffee Connection meeting.","og_url":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2026-05-06T14:00:51+00:00","article_modified_time":"2026-05-11T08:26:25+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: &#8220;We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules&#8221;","datePublished":"2026-05-06T14:00:51+00:00","dateModified":"2026-05-11T08:26:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/"},"wordCount":249,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","keywords":["Nuage Therapeutics"],"articleSection":["PCB"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/","url":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/","name":"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: \"We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules\" - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","datePublished":"2026-05-06T14:00:51+00:00","dateModified":"2026-05-11T08:26:25+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"description":"We interviewed Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics, at the latest edition of the Coffee Connection meeting.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2026\/05\/mini_nuage_noti-1.jpg","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/mireia-pesarrodona-screening-platform-manager-at-nuage-therapeutics-we-have-a-technology-applicable-to-a-type-of-protein-that-allows-us-to-directly-obtain-the-functionality-of-our-molecules\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Mireia Pesarrodona, Screening Platform Manager at Nuage Therapeutics: &#8220;We have a technology applicable to a type of protein that allows us to directly obtain the functionality of our molecules&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=110654"}],"version-history":[{"count":2,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110654\/revisions"}],"predecessor-version":[{"id":110718,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/110654\/revisions\/110718"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/110646"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=110654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=110654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=110654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}